printer-friendly
Publications List by Author
Mukta Arora, MD
Veronika Bachanova, MD
Claudio Brunstein, MD
Linda Burns, MD
Sarah Cooley, MD
Dan Kaufman, MD
Navneet Majhail, MD
Brian McClune, MD
Philip McGlave, MD
Jeffrey Miller, MD
Betul Oran, MD
Arne Slungaard, MD
Gregory Vercellotti, MD
Erica Warlick, MD
Daniel Weisdorf, MD
Mukta Arora, M.D., M.S., Assistant Professor
Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, Defor TE, Dusenbery KE, Kaufman DS, Kersey JH, Macmillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: Analysis of graft sources and long-term outcome. J Clin Oncol. 2009 Jul 6. [Epub ahead of print] PMID: 19581540
Arora M . Therapy of chronic graft-versus-host disease . Best Pract Res Clin Haematol 2008; 21:271-279. PMID: 18503992
Majhail NS, Brunstein CG, McAvoy S, DeFor TE, Al-Hazzouri A, Setubal D, Arora M , Le CT, Wagner JE, Weisdorf DJ. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant. 2008; 14:985-92. PMID: 18721761
Arora M , Nagaraj S, Witte J, Defor TE, Macmillan M, Burns LJ, Weisdorf DJ. New classification of chronic GVHD: Added clarity from the consensus diagnoses . Bone Marrow Transplant. 2009; 43:149-53. PMID: 18794869
Ringden O, Pavletic SZ, Anasetti C, Barrett AJ, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C, Cairo MS, Gale RP, Gupta V, Hahn T, Hale GA, Halter J, Jagasia M, Litzow MR, Locatelli F, Marks DI, McCarthy PL, Cowan MJ, Petersdorf EW, Russell JA, Schiller GJ, Schouten H, Spellman S, Verdonck LF, Wingard JR, Horowitz MM, Arora M . The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation . Blood. 2009; 113:3110-3118. PMID: 19059878
Davies SM, Wang D, Wang T, Arora M , Ringden O, Anasetti C, Pavletic S, Casper J, Macmillan ML, Sanders J, Wall D, Kernan NA. Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants . Biol Blood Marrow Transplant. 2009; 15:360-6. PMID: 19203727
Martin PJ, Storer BE, Rowley SD, Flowers ME, Lee SJ, Carpenter PA, Wingard JR, Shaughnessy PJ, Devetten MP, Jagasia M, Fay JW, van Besien K, Gupta V, Kitko C, Johnston LJ, Maziarz RT, Arora M , Jacobson PA, Weisdorf D. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009 Mar 6. [Epub ahead of print] PMID: 19270260
Ratanatharathorn V, Logan B, Wang D, Horowitz M, Uberti JP, Ringden O, Gale RP, Khoury H, Arora M , Spellman S, Cutler C, Antin J, Bornhaüser M, Hale G, Verdonck L, Cairo M, Gupta V, Pavletic S; for the Center for International Blood and Marrow Transplant Research (CIBMTR), Milwaukee, WI, USA. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol. 2009 Mar 20. [Epub ahead of print] PMID: 19344418
Veronika Bachanova, M.D., Assistant Professor
Bachanova V , Brunstein CG, Burns LJ, Miller JS, Luo X, Defor T, Young JA, Weisdorf DJ, Tomblyn M. Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma . Bone Marrow Transplant. 2009; 43:237-44. PMID: 18806838
Bachanova V , Weisdorf D. Unrelated donor allogeneic transplantation for adult acute lymphoblastic leukemia: a review . Bone Marrow Transplant. 2008; 41:455-464. PMID: 17968329
Bachanova V , Connors JM. How is Hodgkin lymphoma in pregnancy best treated? Hematology Am Soc Hematol Educ Program. 2008; 2008:33-4. PMID: 19074052
Lim W, Arnold DM, Bachanova V , Haspel RL, Rosovsky RP, Shustov AR, Crowther MA. Evidence-based guidelines--an introduction . Hematology Am Soc Hematol Educ Program. 2008;2008:26-30. PMID: 19074050
Bachanova V , McCullar V, Lenvik T, Wangen R, Peterson KA, Ankarlo DE, Panoskaltsis-Mortari A, Wagner JE, Miller JS. Activated notch supports development of cytokine producing NK cells which are hyporesponsive and fail to acquire NK cell effector functions . Biol Blood Marrow Transplant. 2009; 15:183-94. PMID: 19167678
Claudio Brunstein, M.D., Ph.D., Assistant Professor
Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, Defor TE, Dusenbery KE, Kaufman DS, Kersey JH, Macmillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: Analysis of graft sources and long-term outcome. J Clin Oncol. 2009 Jul 6. [Epub ahead of print] PMID: 19581540
Tomblyn M, Brunstein C , Burns LJ, Miller JS, MacMillan M, DeFor TE, Weisdorf DJ. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation . Biol Blood Marrow Transplant. 2008; 14:538-545. PMID: 18410896
Brunstein CG , Barker JN, Weisdorf DJ, Defor TE, McKenna D, Chong SY, Miller JS, McGlave PB, Wagner JE. Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units . Bone Marrow Transplant. 2009 Jan 12. PMID: 19139736.
Brunstein CG , Cantero S, Cao Q, Majhail N, McClune B, Burns LJ, Tomblyn M, Miller JS, Blazar BR, McGlave PB, Weisdorf DJ, Wagner JE. Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation . Biol Blood Marrow Transplant. 2009; 15:214-22. PMID: 19167681
Brunstein CG , Wagner JE, Weisdorf DJ, Cooley S, Noreen H, Barker JN, Defor T, Verneris MR, Blazar BR, Miller JS. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplantation depends on transplantation conditioning intensity . Blood. 2009; 113:5628-34. PMID: 19329778
Majhail NS, Mothukuri JM, Brunstein CG , Weisdorf DJ. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Biol Blood Marrow Transplant. 2009; 15:564-73. PMID: 19361748
Majhail NS, Brunstein CG , McAvoy S, DeFor TE, Al-Hazzouri A, Setubal D, Arora M, Le CT, Wagner JE, Weisdorf DJ. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant. 2008; 14:985-92. PMID: 18721761
Bachanova V, Brunstein CG , Burns LJ, Miller JS, Luo X, Defor T, Young JA, Weisdorf DJ, Tomblyn M. Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma . Bone Marrow Transplant. 2009; 43:237-44. PMID: 18806838
Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, Defor TE, Dusenbery KE, Kaufman DS, Kersey JH, Macmillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: Analysis of graft sources and long-term outcome. J Clin Oncol. 2009 Jul 6. [Epub ahead of print] PMID: 19581540
Majhail NS, Lazarus HM, Burns LJ . Iron overload in hematopoietic cell transplantation . Bone Marrow Transplant. 2008; 41:997-1003. PMID: 18438425
Majhail NS, DeFor T, Lazarus HM, Burns LJ . High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors . Biol Blood Marrow Transplant. 2008; 14:790-794. PMID: 18541198
Majhail NS, Defor TE, Lazarus HM, Burns LJ . Iron-overload after autologous hematopoietic cell transplantation . Leuk Res. 2009; 33:578-9. PMID: 18632150
Bunte MC, Patnaik MM, Pritzker MR, Burns LJ . Pulmonary veno-occlusive disease following hematopoietic stem cell transplantation: a rare model of endothelial dysfunction . Bone Marrow Transplant. 2008; 41:677-686. PMID: 18223697
Kumar P, Defor TE, Brunstein C, Barker JN, Wagner JE, Weisdorf DJ, Burns LJ . Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival . Biol Blood Marrow Transplant. 2008; 14:1394-400. PMID: 19041062
Al-Hazzouri A, Cao Q, Burns LJ , Weisdorf DJ, Majhail NS. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation . Biol Blood Marrow Transplant. 2008; 14:658-653.
Tomblyn M, Brunstein C, Burns LJ , Miller JS, MacMillan M, DeFor TE, Weisdorf DJ. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation . Biol Blood Marrow Transplant. 2008; 14:538-545. PMID: 18410896
Al-Hazzouri A, Cao Q, Burns LJ , Weisdorf DJ, Majhail NS. Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens . Bone Marrow Transplant. 2008 Dec 22; PMID: 19104492
Majhail NS, Flowers ME, Ness KK, Jagasia M, Carpenter PA, Arora M, Arai S, Johnston L, Martin PJ, Baker KS, Lee SJ, Burns LJ . High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation . Bone Marrow Transplant. 2009; 43:49-54. PMID: 18724397
Brunstein CG, Cantero S, Cao Q, Majhail N, McClune B, Burns LJ , Tomblyn M, Miller JS, Blazar BR, McGlave PB, Weisdorf DJ, Wagner JE. Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation . Biol Blood Marrow Transplant. 2009; 15:214-22. PMID: 19167681
Bachanova V, Brunstein CG, Burns LJ , Miller JS, Luo X, Defor T, Young JA, Weisdorf DJ, Tomblyn M. Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma . Bone Marrow Transplant. 2009; 43:237-44. PMID: 18806838
Sarah Cooley, M.D., Assistant Professor
Cooley S , Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, Marsh SG, Guethlein LA, Parham P, Miller JS, Weisdorf DJ. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia . Blood . 2009; 113:726-32. PMID: 18945962
Brunstein CG, Wagner JE, Weisdorf DJ, Cooley S , Noreen H, Barker JN, Defor T, Verneris MR, Blazar BR, Miller JS. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplantation depends on transplantation conditioning intensity . Blood. 2009; 113:5628-34. PMID: 19329778
Dan Kaufman, M.D., Assistant Professor
Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, Defor TE, Dusenbery KE, Kaufman DS, Kersey JH, Macmillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: Analysis of graft sources and long-term outcome. J Clin Oncol. 2009 Jul 6. [Epub ahead of print] PMID: 19581540
Hill KL, Kaufman DS . Hematopoietic differentiation of human embryonic stem cells by cocultivation with stromal layers . Curr Protoc Stem Cell Biol. 2008; Chapter 1:Unit 1F 6. PMID: 18819084
Martin CH, Woll PS, Ni Z, Zuniga-Pflucker JC, Kaufman DS . Differences in lymphocyte developmental potential between human embryonic stem cell and umbilical cord blood-derived hematopoietic progenitor cells . Blood. 2008; 112:2730-2737. PMID: 18621931
Tian X, Kaufman DS . Differentiation of embryonic stem cells towards hematopoietic cells: progress and pitfalls . Curr Opin Hematol. 2008; 15:312-318. PMID: 18536568
Cameron CM, Harding F, Hu WS, Kaufman DS . Activation of hypoxic response in human embryonic stem cell-derived embryoid bodies . Exp Biol Med (Maywood). 2008; 233:1044-1057. PMID: 18535160
Tian X, Kaufman DS . Hematopoietic development of human embryonic stem cells in culture . Methods Mol Biol. 2008; 430:119-133. PMID: 18370295
Woll PS, Morris JK, Painschab MS, Marcus RK, Kohn AD, Biechele TL, Moon RT, Kaufman DS . Wnt signaling promotes hematoendothelial cell development from human embryonic stem cells . Blood. 2008; 111:122-131. PMID: 17875805
Woll PS, Grzywacz B, Tian X, Marcus RK, Knorr DA, Verneris MR, Kaufman DS . Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo anti-tumor activity. Blood. 2009 Apr 13. [Epub ahead of print] PMID: 19365083
Navneet Majhail, M.D., M.S., Assistant Professor
Majhail NS , Flowers ME, Ness KK, Jagasia M, Carpenter PA, Arora M, Arai S, Johnston L, Martin PJ, Baker KS, Lee SJ, Burns LJ. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation . Bone Marrow Transplant. 2009; 43:49-54. PMID: 18724397
Majhail NS , Brunstein CG, McAvoy S, DeFor TE, Al-Hazzouri A, Setubal D, Arora M, Le CT, Wagner JE, Weisdorf DJ. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant. 2008; 14:985-92. PMID: 18721761
Majhail NS , DeFor T, Lazarus HM, Burns LJ. High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors . Biol Blood Marrow Transplant. 2008; 14:790-794. PMID: 18541198
Majhail NS , Defor TE, Lazarus HM, Burns LJ. Iron-overload after autologous hematopoietic cell transplantation . Leuk Res. 2009; 33:578-9. PMID: 18632150
Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ, Majhail NS . Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation . Biol Blood Marrow Transplant. 2008; 14:658-653.
Majhail NS , Lazarus HM, Burns LJ. Iron overload in hematopoietic cell transplantation . Bone Marrow Transplant. 2008; 41:997-1003. PMID: 18438425
Majhail NS , Brunstein CG, Tomblyn M, Thomas AJ, Miller JS, Arora M, Kaufman DS, Burns LJ, Slungaard A, McGlave PB, Wagner JE, Weisdorf DJ. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor . Biol Blood Marrow Transplant. 2008; 14:282-289. PMID: 18275894
Majhail NS . Old and new cancers after hematopoietic-cell transplantation . Hematology Am Soc Hematol Educ Program. 2008; 2008:142-9. PMID: 19074072
Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ, Majhail NS . Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens . Bone Marrow Transplant. 2008 Dec 22; [Epub ahead of print] PMID: 19104492
Brunstein CG, Cantero S, Cao Q, Majhail N , McClune B, Burns LJ, Tomblyn M, Miller JS, Blazar BR, McGlave PB, Weisdorf DJ, Wagner JE. Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation . Biol Blood Marrow Transplant. 2009; 15:214-22. PMID: 19167681
Majhail NS , Mothukuri JM, Brunstein CG, Weisdorf DJ. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Biol Blood Marrow Transplant. 2009; 15:564-73. PMID: 19361748
Majhail NS , Brunstein CG, McAvoy S, DeFor TE, Al-Hazzouri A, Setubal D, Arora M, Le CT, Wagner JE, Weisdorf DJ. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant. 2008; 14:985-92. PMID: 18721761
Brian McClune, D.O., Assistant Professor
Przepiorka D, Buadi FK, McClune B . Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia . Pharmacotherapy. 2008;28:58-63. PMID: 18154475
Brunstein CG, Cantero S, Cao Q, Majhail N, McClune B , Burns LJ, Tomblyn M, Miller JS, Blazar BR, McGlave PB, Weisdorf DJ, Wagner JE. Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation . Biol Blood Marrow Transplant. 2009; 15:214-22. PMID: 19167681
Philip McGlave, M.D., Professor
Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, Defor TE, Dusenbery KE, Kaufman DS, Kersey JH, Macmillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: Analysis of graft sources and long-term outcome. J Clin Oncol. 2009 Jul 6. [Epub ahead of print] PMID: 19581540
Brunstein CG, Barker JN, Weisdorf DJ, Defor TE, McKenna D, Chong SY, Miller JS, McGlave PB , Wagner JE. Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units . Bone Marrow Transplant. 2009 Jan 12. PMID: 19139736.
Brunstein CG, Cantero S, Cao Q, Majhail N, McClune B, Burns LJ, Tomblyn M, Miller JS, Blazar BR, McGlave PB , Weisdorf DJ, Wagner JE. Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation . Biol Blood Marrow Transplant. 2009; 15:214-22. PMID: 19167681.
Jeffrey Miller, M.D., Professor
Miller JS . How killers kill . Blood. 2008; 112:213. PMID: 18606880
Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, Defor TE, Dusenbery KE, Kaufman DS, Kersey JH, Macmillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: Analysis of graft sources and long-term outcome. J Clin Oncol. 2009 Jul 6. [Epub ahead of print] PMID: 19581540
Dudek AZ, Mescher MF, Okazaki I, Math VT, Luo X, Curtsinger JM, Miller JS . Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma . Am J Clin Oncol. 2008; 31:173-181. PMID: 18391603
McCullar V, Oostendorp R, Panoskaltsis-Mortari A, Yun G, Lutz CT, Wagner JE, Miller JS . Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15 . Exp Hematol. 2008; 36:598-608. PMID: 18295962
Cichocki F, Hanson RJ, Lenvik T, Pitt M, McCullar V, Li H, Anderson SK, Miller JS . The transcription factor c-Myc enhances KIR gene transcription through direct binding to an upstream distal promoter element . Blood. 2009; 113:3245-53 . PMID: 18987359
Tomblyn M, Brunstein C, Burns LJ, Miller JS , MacMillan M, DeFor TE, Weisdorf DJ. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation . Biol Blood Marrow Transplant. 2008; 14:538-545. PMID: 18410896
Brunstein CG, Barker JN, Weisdorf DJ, Defor TE, McKenna D, Chong SY, Miller JS , McGlave PB, Wagner JE. Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units . Bone Marrow Transplant. 2009 Jan 12. PMID: 19139736.
Brunstein CG, Cantero S, Cao Q, Majhail N, McClune B, Burns LJ, Tomblyn M, Miller JS , Blazar BR, McGlave PB, Weisdorf DJ, Wagner JE. Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation . Biol Blood Marrow Transplant. 2009; 15:214-22. PMID: 19167681
Bachanova V, McCullar V, Lenvik T, Wangen R, Peterson KA, Ankarlo DE, Panoskaltsis-Mortari A, Wagner JE, Miller JS . Activated notch supports development of cytokine producing NK cells which are hyporesponsive and fail to acquire NK cell effector functions . Biol Blood Marrow Transplant. 2009; 15:183-94. PMID: 19167678
Brunstein CG, Wagner JE, Weisdorf DJ, Cooley S, Noreen H, Barker JN, Defor T, Verneris MR, Blazar BR, Miller JS . Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplantation depends on transplantation conditioning intensity . Blood. 2009; 113:5628-34. PMID: 19329778
Miller JS . Should natural killer cells be expanded in vivo or ex vivo to maximize their therapeutic potential? Cytotherapy. 2009; 6:1-2. PMID: 19347766
Hummon D, Zantek ND, Sumstad D, Miller JS , McKenna DH. Transfusion-associated graft-versus-host disease: a perspective from a cell therapy laboratory. Transfusion. 2009;49:1018-9. PMID: 19426202
Bachanova V, Brunstein CG, Burns LJ, Miller JS , Luo X, Defor T, Young JA, Weisdorf DJ, Tomblyn M. Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma . Bone Marrow Transplant. 2009; 43:237-44. PMID: 18806838
Alter G, Rihn S, Walters K, Nolting A, Martin M, Rosenberg ES, Miller JS, Carrington M, Altfeld M. HLA class I subtype dependent expansion of KIR3DS1 + and KIR3DL1 + NK cells during acute HIV-1 infection . Jvirol.2009 Apr 22. [Epub ahead of print] PMID: 19386717
Betul Oran, M.D., M.S., Assistant Professor
Van Biesen K, Kunavakkam R, Rondon G, De Lima M, Artz A, Oran B , Giralt S. Fludarabine-melphalan conditioning for AML and MDS: Alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes . BBMT 2009;15:610-617. PMID: 19361753
Rosenzweig M, Seldin DC, Remick DG, Skinner M, Quillen K, Oran B , Finn KT, Sanchorawala V. Febrile reactions occurring with second cycle of high dose melphalan and SCT in patients with AL amyloidosis:a“melphalan recall” reaction . BMT 2009; In press. PMID: 19421171
Arne Slungaard, M.D., Professor
Li YD, Ye BQ, Zheng SX, Wang JT, Wang JG, Chen M, Liu JG, Pei XH, Wang LJ, Lin ZX, Gupta K, Mackman N, Slungaard A , Key NS, Geng JG. NF-kappa B transcription factor p50 critically regulates tissue factor in deep vein thrombosis . J Biol Chem. 2009; 284:4473-83. PMID: 19095643
Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, Defor TE, Dusenbery KE, Kaufman DS, Kersey JH, Macmillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: Analysis of graft sources and long-term outcome. J Clin Oncol. 2009 Jul 6. [Epub ahead of print] PMID: 19581540
Gregory Vercellotti, M.D., F.A.C.P., Professor
Bruzzone CM, Belcher JD, Schuld NJ, Newman KA, Vineyard J, Nguyen J, Chen C, Beckman JD, Steer CJ, Vercellotti GM . Quantitative real-time polymerase chain reaction (qRT-PCR) restriction fragment length polymorphism (RFLP) method for monitoring highly conserved transgene expression during gene therapy . Transl Res. 2008; 152: 290-7. PMID: 19059164
Cunningham JM, Patnaik MM, Hammerschmidt DE, Vercellotti GM . Historical perspective and clinical implications of the Pelger-Huet cell . Am J Hematol. 2009; 84:116-9. PMID: 19021122
Jeney V, Komódi E, Nagy E, Zarjou A, Vercellotti GM , Eaton JW, Balla G, Balla J. Suppression of hemin-mediated oxidation of low-density lipoprotein and subsequent endothelial reactions by hydrogen sulfide (H(2)S) . Free Radic Biol Med. 2009; 46:616-23. PMID: 19100829
Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, Defor TE, Dusenbery KE, Kaufman DS, Kersey JH, Macmillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: Analysis of graft sources and long-term outcome. J Clin Oncol. 2009 Jul 6. [Epub ahead of print] PMID: 19581540
Erica Warlick, M.D., Assistant Professor
Warlick ED , O'Donnell PV, Borowitz M, Grupka N, Decloe L, Garrett-Mayer E, Borrello I, Brodsky R, Fuchs E, Huff CA, Luznik L, Matsui W, Ambinder R, Jones RJ, Douglas Smith B. Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes . Leuk Res. 2008; 32:1439-1447. PMID: 18261793
Warlick ED , Cioc A, Defor T, Dolan M, Weisdorf D. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden . Biol Blood Marrow Transplant. 2009; 15:30-8. PMID: 19135940
Daniel Weisdorf, M.D., Professor
Arora M, Nagaraj S, Witte J, Defor TE, Macmillan M, Burns LJ, Weisdorf DJ . New classification of chronic GVHD: Added clarity from the consensus diagnoses . Bone Marrow Transplant. 2009; 43:149-53. PMID: 18794869
Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, Defor TE, Dusenbery KE, Kaufman DS, Kersey JH, Macmillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: Analysis of graft sources and long-term outcome. J Clin Oncol. 2009 Jul 6. [Epub ahead of print] PMID: 19581540
Levine JE, Blazar BR, DeFor T, Ferrara JL, Weisdorf DJ . Long-term follow-up of a phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT) . Biol Blood Marrow Transplant. 2008; 14:1017-1021. PMID: 18721764
Majhail NS, Brunstein CG, McAvoy S, DeFor TE, Al-Hazzouri A, Setubal D, Arora M, Le CT, Wagner JE, Weisdorf DJ . Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant. 2008; 14:985-92. PMID: 18721761
Tomblyn M, Brunstein C, Burns LJ, Miller JS, MacMillan M, DeFor TE, Weisdorf DJ . Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation . Biol Blood Marrow Transplant. 2008; 14:538-545. PMID: 18410896
Marks DI, Perez WS, He W, Zhang MJ, Biship MR, Bolwell BJ, Bredeson CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Jakubowski AA, Keating A, Klumpp TR, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernik PH, Weisdorf DJ . Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission . Blood. 2008; 112:426-434. PMID: 18398065
Majhail NS, Brunstein CG, Tomblyn M, Thomas AJ, Miller JS, Arora M, Kaufman DS, Burns LJ, Slungaard A, McGlave PB, Wagner JE, Weisdorf DJ . Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor . Biol Blood Marrow Transplant. 2008; 14:282-289. PMID: 18275894
Bishop MR, Logan BR, Gandham S, Bolwell BJ, Cahn JY, Lazarus HM, Litzow MR, Marks DI, Wiernik PH, McCarthy PL, Russell JA, Miller CB, Sierra J, Milone G, Keating A, Loberiza FR Jr, Giralt S, Horowitz MM, Weisdorf DJ . Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research . Bone Marrow Transplant. 2008; 41:635-642. PMID: 18084335
Dehn J, Arora M, Spellman S, Setterholm M, Horowitz M, Confer D, Weisdorf D . Unrelated donor hematopoietic cell transplantation: Factors associated with a better HLA match . Biol Blood Marrow Transplant. 2008; 14: 1334-40. PMID: 19041054
Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, Marsh SG, Guethlein LA, Parham P, Miller JS, Weisdorf DJ . Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia . Blood . 2009; 113:726-32. PMID: 18945962
Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ , Majhail NS. Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens . Bone Marrow Transplant. 2008 Dec 22; [Epub ahead of print] PMID: 19104492
Bachanova V, Weisdorf D . Unrelated donor allogeneic transplantation for adult acute lymphoblastic leukemia: a review . Bone Marrow Transplant. 2008; 41:455-464. PMID: 17968329
Majhail NS, Brunstein CG, McAvoy S, DeFor TE, Al-Hazzouri A, Setubal D, Arora M, Le CT, Wagner JE, Weisdorf DJ . Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant. 2008; 14:985-92. PMID: 18721761
Brunstein CG, Barker JN, Weisdorf DJ , Defor TE, McKenna D, Chong SY, Miller JS, McGlave PB, Wagner JE. Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units . Bone Marrow Transplant. 2009 Jan 12. PMID: 19139736.
Brunstein CG, Cantero S, Cao Q, Majhail N, McClune B, Burns LJ, Tomblyn M, Miller JS, Blazar BR, McGlave PB, Weisdorf DJ , Wagner JE. Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation . Biol Blood Marrow Transplant. 2009; 15:214-22. PMID: 19167681
Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D , Territo M, Badel K, Calandra G. Treatment with Plerixa for in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: Implications for the heavily pretreated patient . Biol Blood Marrow Transplant. 2009; 15:249-56. PMID: 19167685
Burke MJ, Trotz B, Luo X, Weisdorf DJ , Baker KS, Wagner JE, Verneris MR. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (Allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients . Bone Marrow Transplant. 2009 Feb 9. [Epub ahead of print] PMID: 19204709
Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D . Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden . Biol Blood Marrow Transplant. 2009; 15:30-8. PMID: 19135940
Brunstein CG, Wagner JE, Weisdorf DJ , Cooley S, Noreen H, Barker JN, Defor T, Verneris MR, Blazar BR, Miller JS. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplantation depends on transplantation conditioning intensity . Blood. 2009; 113:5628-34. PMID: 19329778
Hari PN, Zhang MJ, Roy V, Pérez WS, Bashey A, To LB, Elfenbein G, Freytes CO, Gale RP, Gibson J, Kyle RA, Lazarus HM, McCarthy PL, Milone GA, Pavlovsky S, Reece DE, Schiller G, Vela-Ojeda J, Weisdorf D , Vesole D. Is the international staging system superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant . Leukemia. 2009 Mar 26.[Epub ahead of print] PMID: 19322205
Martin PJ, Storer BE, Rowley SD, Flowers ME, Lee SJ, Carpenter PA, Wingard JR, Shaughnessy PJ, Devetten MP, Jagasia M, Fay JW, van Besien K, Gupta V, Kitko C, Johnston LJ, Maziarz RT, Arora M, Jacobson PA, Weisdorf D . Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease . Blood. 2009; 113:5074-82. PMID: 19270260
Alousi AM, Weisdorf DJ , Logan BR, Bolanos-Meade J, Carter S, Difronzo N, Pasquini M, Goldstein SC, Ho VT, Hayes-Lattin B, Wingard JR, Horowitz MM, Levine JE. Etanercept, mycophenolate, denileukin or pentostatin plus corticosteroids for acute graft vs. host disease: a randomized phase II trial from the BMT CTN. Blood. 2009 May 14. PMID: 19443659
Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ . Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Biol Blood Marrow Transplant. 2009; 15:564-73. PMID: 19361748
Bachanova V, Brunstein CG, Burns LJ, Miller JS, Luo X, Defor T, Young JA, Weisdorf DJ , Tomblyn M. Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma . Bone Marrow Transplant. 2009; 43:237-44. PMID: 18806838
